A Study of Mosliciguat in PH-ILD

ClinicalTrials.gov ID: NCT06635850

Public ClinicalTrials.gov record NCT06635850. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Sep 4, 2026, 6:11 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 2, Randomized, Placebo-Controlled Trial to Assess the Efficacy and Safety of Mosliciguat in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This is a Phase 2, randomized, double-blind, placebo-controlled, multi-center clinical study to evaluate the safety and efficacy of inhaled mosliciguat in participants with pulmonary hypertension associated with interstitial lung disease (PH-ILD).

Study identification

NCT ID: NCT06635850
Recruitment status: Active, not recruiting
Study type: Interventional
Phase: Phase 2
Lead sponsor: Pulmovant, Inc.; Industry
Enrollment: 135 participants

Conditions and interventions

Conditions

Interventions

Drug · Device

Eligibility (public fields only)

Age range: 18 Years to 85 Years
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Oct 28, 2024
Primary completion: Nov 30, 2026
Completion: Dec 31, 2027
Last update posted: Feb 19, 2026

2024 – 2028

United States locations

U.S. sites: 18
U.S. states: 15
U.S. cities: 18

Facility	City	State	ZIP	Site status
Arizona Pulmonary Specialists	Phoenix	Arizona	85012	—
Ronald Reagan UCLA Medical Center	Los Angeles	California	90024	—
University of California Davis School of Medicine	Sacramento	California	95817	—
Harbor-UCLA Medical Center - Torrance	Torrance	California	90502	—
Florida Lung, Asthma & Sleep Specialists/Clinical Research Specialists, LLC	Celebration	Florida	34746	—
Northwestern University	Chicago	Illinois	60026	—
University of Iowa Hospitals and Clinics	Iowa City	Iowa	52242	—
University of Kansas Medical Center	Kansas City	Kansas	66160	—
Norton Pulmonary Specialists	Louisville	Kentucky	40202	—
Duke University Health System - Duke Clinic	Durham	North Carolina	27710	—
PulmonIx	Greensboro	North Carolina	27403	—
Hoxworth Blood Center	Cincinnati	Ohio	45267	—
Summit Health	Bend	Oregon	97701	—
Lewis Katz School of Medicine	Philadelphia	Pennsylvania	19140	—
Brown Medicine	East Providence	Rhode Island	02915	—
Medical University of South Carolina	Charleston	South Carolina	29425	—
Houston Methodist Lung Center	Houston	Texas	77030	—
University of Utah Health	Salt Lake City	Utah	84132-0001	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT06635850, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Feb 19, 2026 · Synced Sep 4, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT06635850 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →